- Intermap Technologies Corporation (IMP)
- Medicenna Therapeutics Corp. (MDNA)
- Perpetua Resources Corp. (PPTA)
- Anaergia Inc. (ANRG)
ANRG experienced a 'recover from death' bounce in 2024 and we would not expect a repeat performance here. IMP has been around a long time and finally saw some traction. But its revenue base remains very low and at 11X sales we would not expect a similar year. MDNA has some cash but no revenue, and results are going to depend on trials, which we cannot really predict. We would expect some consolidation. PPTA is the largest, and with solid, famous shareholders backing it, and in the right sector, likely has a decent chance of continuing to do well.